Risk factors and outcomes for the development of malignancy in lung and heart-lung transplant recipients

Canadian Respiratory Journal

Volumn 17, Issue 1, 2010, Pages

  Metcalfe, Michael J ^a   Kutsogiannis, Demetrios J ^a   Jackson, Kathy ^a   Oreopoulous, Antigone ^a   Mullen, John ^a   Modry, Denis ^a   Weinkauf, Justin ^a   Lien, Dale C ^a   Stewart, Ken C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Heart and lung transplantation; Lung transplantation; Malignancy; Outcome; Risk factor; Thoracic transplantation

Indexed keywords

ADULT; AGE; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CAUSE OF DEATH; CIGARETTE SMOKING; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DISEASE; HEART LUNG TRANSPLANTATION; HUMAN; LUNG DISEASE; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; ORGAN DONOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL TIME;

EID: 77953992361     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/183936     Document Type: Article

References (25)

1. Hosenpud J, Bennett L, Keck B, Edwards E, Novick R. Effect ofdiagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:9095.
2. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of patient survival benefit after lung transplantation by patient diagnosis. J Heart Lung Tranplant 2002;24:968-82.
3. Geertsma A, ten Verget EM, Bonsel JG, de Boer WJ, Vander BW. Does lung transplantation prolong life? A comparison of survival with and without transplantation. J Heart Lung Transplant 1998;17:511-6.
4. Adami J, Gabel H, Lindelof B, et al. Cancer risk following solid organ transplantation: A nationwide cohort in Sweden. Br J Cancer 2003;89:1221-7.
5. Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation 2006;4:547-51.
6. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-third Official Adult Lung and Heart-Lung Transplantation Report - 2006. J Heart Lung Tranplantation 2006;25:880-92.
7. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 2007;67:1167-98.
8. Knoop C, Haverich A, Fisher S. Immunosuppressive therapy after human lung transplantation. Eur Resp J 2004;23:159-71.
9. Roithmaier S, Haydon AM, Loi S. Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience. J Heart Lung Transplant 2007;26:845-9.
10. Campbell A, Moazami N, Ditkoff BA, Kurtz E, Estabrook A, Schnabel F. Short-term outcome of chronic immunosuppression on the development of breast lesions in premenopausal heart and lung transplant patients. J Surg Res 1998;78:27-30.
11. de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003;75:361-7.
12. Dickson RP, Davis RD, Rea JB, et al. High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant 2006;25:1297-301.
13. Collins J, Kazeroni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: Frequency, clinical characteristics, and imaging findings. Radiology 2002;224:131-8.
14. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Tranpslant 2001;20:1044-53.
15. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000;11:753-9.
16. Robson RR, Robson JM, Cecka G, Budde OM, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5:2954-60.
17. O'neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:1186-91.
18. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994;15:568-73.
19. Blaheta RA, Bogossian H, Beecken WD, et al. Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro. Transplantation 2003;27:1735-41.
20. Delgado JF, Crespo MG, Pulpon LA, et al. Pre-existing neoplasms and risk for malignancy after heart transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry. J Heart Lung Transplant 2007;26:S124-5.
21. Koerner MM, Tenderich G, Minami K, et al. Results of heart transplantation in patients with pre-existing malignancies. Am J Cardiol 1997;79;988-91.
22. Ladowski SD, Abel M, Beatty L, et al. Long-term follow-up of heart transplant recipients with pre-transplant malignancies. Tex Heart Inst J 2006;33:27-30.
23. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-7.
24. Villanueva J, Garrity E. How to select patients for lung transplantation: Guidelines for recognizing appropriate candidates in time for success. J Crit Ill 2001;16:126-32.
25. Orens JB, Estenne ME, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25;745-55.